Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI India ETF (INDA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

iShares MSCI India ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

iShares MSCI India ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI India ETF trades at $49.68, while State Street SPDR S&P Biotech ETF trades at $159.65. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.

INDAXBI
Sector
Broad Market / FactorBroad Market / Factor
52-Week High
$55.29$164.28
52-Week Low
$45.42$88.79

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI India ETF

INDA trades at $49.95, down 0.38% with a bullish technical signal supported by moving averages. The ETF tracks India's market, which grew 7.8% in Q1 2026 (CNBC, June 5, 2026), but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Key support and resistance cluster around $50.

Outlook remains mixed: India's strong economic growth offers long-term potential, but near-term risks include Middle East disruptions affecting exports (Reuters, August 4, 2026) and AI-driven pressure on IT firms. Institutional sentiment is cautious amid foreign capital rotation.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

About iShares MSCI India ETF

INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.

Read more on INDA

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI